Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 trial of Takeda dengue tetravalent live attenuated vaccine (TDV) in healthy Japanese adults, adolescents, and children
jRCT2071240088Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dengue tetravalent vaccine, live, attenuated in dengue fever (3 arms), sponsored by Takeda. Primary endpoint: Percentage of seropositive participants for each dengue virus serotype on Day 120. Started Jan 2025; status: completed.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on jRCT2071240088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240088.